Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Lab Diagnostic Systems (SMC) Pvt. Ltd.

Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx42product presentations
G24generic molecules
DF5dosage-form groups
TA0therapeutic areas
PKR42current price records
REG36registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage93%
priced packs safely normalized per unit
Comparable-market coverage60%
products with at least one like-for-like comparator
Portfolio intelligence

Therapeutic mix

Unclassified42 products · 100%
Formulation footprint

Dosage forms

Injection29 products
Capsule5 products
Tablet5 products
Vaccine2 products
Infusion1 products
Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 DocesoleDocetaxel 3presentations 120 mg/6 mL, 20 mg/mL, 80 mg/4 mL · Injection #2 ImatinibImatinib 3presentations 100 mg · Tablet #3 VINOXEnoxaparin 3presentations 40 mg, 60 mg, 80 mg · Injection #4 ZaxolPaclitaxel (albumin-bound nanoparticles) 3presentations 100 mg/16.7 mL, 30 mg/5 mL, 300 mg/50 mL · Injection #5 ActLouvikaIbrutinib 2presentations 140 mg · Capsule #6 BioShootRabies vaccine, inactivated (purified Vero cell) 2presentations 2.5 IU · Vaccine
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median728% of comparable products
Near market median14within ±5% of median
Above market median416% of comparable products
Lowest-price equivalents14ties included
Company median price position -2.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Neonib 200 mgNilotinib · Capsule · 28's PKR 2,039.64/capsule-34.6% vs market median Neonib 200 mgNilotinib · Capsule · 112's PKR 2,039.67/capsule-34.6% vs market median Imatinib 100 mgImatinib · Tablet · 30's PKR 815.46/tablet-26.1% vs market median Imatinib 100 mgImatinib · Tablet · 120's PKR 849.39/tablet-23.0% vs market median Imatinib 100 mgImatinib · Tablet · 10's PKR 849.44/tablet-23.0% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

AJ Mirza Pharma Pvt Ltd109 products · 56 generics 11shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 10shared generics Himmel Pharmaceuticals Private Limited49 products · 23 generics 10shared generics Helix Pharma (Pvt)., Ltd.113 products · 45 generics 7shared generics Oncogen Pharma (Pvt) Limited21 products · 9 generics 7shared generics Pharmedic Laboratories (Pvt.) Ltd Lahore122 products · 70 generics 6shared generics
Regulatory & price activity

Observed database signals

Registration numbers36
Price-history records48
Products with price history5
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation9 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

42 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Zolon 100 Oxaliplatin 100 mg/50 mL Injection 1's Vial 122414 PKR 36,644.88 PKR 36,644.88/vial/unit No comparator
Zolon 50 Oxaliplatin 50 mg/25 mL Injection 1's Vial 122413 PKR 18,322.45 PKR 18,322.45/vial/unit Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.